A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Clolar (clofarabine injection) is approved by the Food and Drug Administration (FDA) for the
treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia
(ALL) who have had at least 2 prior treatment regimens.
This study will evaluate the efficacy of clofarabine in elderly patients with acute
myelogenous leukemia (AML) who are unlikely to benefit from treatment with intensive
chemotherapy regimens (cytarabine and anthracycline based regimens) used in younger patients
with AML.